Protocol digest of a randomized controlled trial comparing transverse colectomy with extended right hemicolectomy for Stage II/III transverse colon cancer: JCOG2304 (TACTICS) [0.03%]
II期和III期横结肠癌患者行横结肠切除术与扩大右半结肠切除术的前瞻性随机对照试验方案摘要：JCOG2304（TACTICS）研究
Tetsuya Sekita,Tomonori Akagi,Ryo Sadachi et al.
Tetsuya Sekita et al.
Transverse colon cancer is traditionally treated with extended right hemicolectomy (EHC), which involves division of the middle colic, right colic, and ileocolic arteries, along with removal of the terminal ileum and right colon. Transverse...
Efficacy and safety of multimodality therapy stratified by resection rate and molecular markers in children and adolescents with ependymoma: JCCG EPN23 protocol [0.03%]
基于切除率和分子标记的多模式治疗儿童和青少年ependymoma疗效及安全性的JCCG EPN23方案
Rieko Taniguchi,Yoshiki Shiba,Fumiharu Ohka et al.
Rieko Taniguchi et al.
Background: Ependymomas are rare pediatric brain tumors characterized by clinical and molecular heterogeneity. The JCCG EPN23 study is a nationwide prospective trial in Japan designed to evaluate outcomes of risk-adapted ...
Burden of disease-specific late effects after proton beam therapy in pediatric solid and CNS tumor survivors: a single-institution survey in Japan [0.03%]
日本单中心质子治疗后儿科实体瘤和中枢神经系统肿瘤患者的疾病特异性晚期效应负担：一项机构调查
Hiroko Fukushima,Sho Hosaka,Ryoko Suzuki et al.
Hiroko Fukushima et al.
Background: Proton beam therapy (PBT) has been increasingly adopted in pediatric oncology to reduce radiation-related toxicity; however, its long-term comorbidities remain incompletely understood. Because tumor types and ...
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy [0.03%]
一线免疫联合治疗转移性透明细胞肾细胞癌老年患者的预后模型的建立
Shinya Watanabe,Yuto Matsushita,Yuya Oishi et al.
Shinya Watanabe et al.
Background: In the era of immuno-oncology (IO) combination therapy, prognostic tools for elderly patients with metastatic clear cell renal cell carcinoma (ccRCC) are lacking. This study aimed to identify prognostic factor...
Clinical utility of tumour markers in skeletal metastasis of unknown primary at the initial visit [0.03%]
初次就诊时不明原发灶骨骼转移肿瘤标志物的临床应用价值
Kensaku Yamaga,Keiichi Akahori,Mari Osaki et al.
Kensaku Yamaga et al.
Background: Skeletal metastasis of unknown primary at the initial visit represents a clinically important subset of metastatic bone tumours, accounting for ~7.8%-21.7% of all skeletal metastases. This condition differs fr...
Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma [0.03%]
根治性肾输尿管全长切除术中膀胱活检对上尿路尿路上皮癌患者膀胱复发率的不利影响
Tomonori Kanagawa,Ichiro Yonese,Takehiro Nakamura et al.
Tomonori Kanagawa et al.
Introduction: Seeding and implantation are major mechanisms of intravesical recurrence (IVR) following the radical nephroureterectomy (RNU) of upper tract urothelial carcinoma (UTUC). We herein hypothesized that bladder b...
POU2F3 expression in lung squamous cell carcinoma: transcriptomic and immunohistochemical profiling with prognosis [0.03%]
肺鳞状细胞癌中POU2F3的表达：转录组和免疫组织化学特征及预后分析
Suguru Mitsui,Naoe Jimbo,Hiroyuki Ogawa et al.
Suguru Mitsui et al.
Background: Lung squamous cell carcinoma (LUSC) lacks well-defined molecular targets. This study investigated the clinical and biological relevance of POU class 2 homeobox 3 (POU2F3), a tuft cell-associated transcription ...
Age-standardized mortality-to-incidence ratio for larynx cancer in the world [0.03%]
全球喉癌年龄标准化死亡与发病率比值
Sumiyo Okawa,Hadrien Charvat
Sumiyo Okawa
Correction to: Reclassification of a BRCA2 variant, c.8487G > A (p.Gln2829Gln) located at 3' end of exon 19, from uncertain significance to likely pathogenic based on splicing alteration: a case report [0.03%]
对BRCA2变异c.8487G>A(p.Gln2829Gln):基于剪接改变的外显子19′端重新分类从意义未明到很可能致病：病例报告
Published Erratum
Japanese journal of clinical oncology. 2026 May 4:hyag082. DOI:10.1093/jjco/hyag082 2026